Supernus Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02023606
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT01994109
Open-Label, Extension Study to 810P202
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT01416064
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT01364662
Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2016-06-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01284530
A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01114854
- Locations
- 🇺🇸
Dr. Segal, Fort Lauderdale, Florida, United States
🇺🇸Kyle Patrick, Phoenix, Arizona, United States
🇺🇸Dr. Chumley, Lexington, Kentucky, United States
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01107496
Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00918047
Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
- Conditions
- First Posted Date
- 2009-06-11
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Registration Number
- NCT00918424
- Locations
- 🇺🇸
Site 03, Loxahatchee Groves, Florida, United States
🇺🇸Site 07, San Antonio, Texas, United States
🇺🇸Site 05, Rochester, New York, United States
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00908349
© Copyright 2024. All Rights Reserved by MedPath